backKing & Spalding invites you to join a discussion on recent developments concerning parallel imports.
Parallel imports of pharmaceuticals and medical devices make up market shares of up to 40% in Germany. This leads to increased awareness among brand owners and original manufacturers. With the Falsified Medicines Directive, parallel traders saw a great opportunity to henceforth use their own packages at low cost ("reboxing"), which may lead to significant changes in the product. The ECJ has ruled in principle with 3 decisions dated 17.11.2022.
We look forward to discussing with you the opportunities that these ECJ rulings present for original manufacturers.
Please contact freichard@kslaw.com if you have any questions.